Literature DB >> 2341832

Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1.

P Reiss1, J M Lange, A de Ronde, F de Wolf, J Dekker, C Debouck, J Goudsmit.   

Abstract

Antibodies to E. coli-produced HIV-1 nef, rev, tat, vpu, and vpr proteins were measured by enzyme immunoassay in serial sets of sera from 72 men seroconverting for antibodies to HIV-1 structural proteins, and from 190 initially symptom-free men who were seropositive for these antibodies at entry into the study. In the men seroconverting for antibodies to structural proteins the levels of nef-, rev-, and tat-specific antibodies, but not of vpu-, and vpr-specific antibodies, within 3 months of seroconversion, appeared to be lower in the five men progressing to AIDS, compared with the men remaining symptom-free during follow-up. Analysis of the prevalence of previously described antibody profiles to these accessory gene products was carried out. In all HIV-1 antibody seroconverters and in those HIV-1 antibody seropositive men with 15 or more months of follow-up who progressed to AIDS, there was a shift from predominantly nef- and vpu-specific antibody negative profiles in the men developing AIDS in the early years of the study to predominantly nef- and vpu-specific antibody positive profiles in men who developed AIDS later. Rev- and tat-specific antibody negative profiles were dominant in men progressing to AIDS throughout follow-up. No vpr-specific antibody profile occurred preferentially in the men progressing to AIDS throughout follow-up. Low antibody reactivity to accessory gene products nef, rev, and tat appears, like low anti-core antibody reactivity, to be associated with progression to AIDS relatively rapidly after infection with HIV-1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2341832     DOI: 10.1002/jmv.1890300303

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  17 in total

1.  Characterization of Nef-CXCR4 interactions important for apoptosis induction.

Authors:  Ming-Bo Huang; Ling Ling Jin; Cleve O James; Mahfuz Khan; Michael D Powell; Vincent C Bond
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

2.  Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.

Authors:  Laurent Mascarell; Catherine Fayolle; Cécile Bauche; Daniel Ladant; Claude Leclerc
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Short communication: circulating plasma HIV-1 viral protein R in dual HIV-1/tuberculosis infection.

Authors:  Zahra Toossi; Shigou Liu; Mianda Wu; Harriet Mayanja-Kizza; Christina S Hirsch
Journal:  AIDS Res Hum Retroviruses       Date:  2014-06-10       Impact factor: 2.205

4.  Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients.

Authors:  M C Re; G Furlini; M Vignoli; E Ramazzotti; G Zauli; M La Placa
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

5.  Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.

Authors:  T C Rodman; S E To; H Hashish; K Manchester
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

6.  Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.

Authors:  Ruth H Florese; Thorsten Demberg; Peng Xiao; LaRene Kuller; Kay Larsen; L Ebonita Summers; David Venzon; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

7.  Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.

Authors:  N K Back; L Smit; M Schutten; P L Nara; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Antibody to HIV-1 Tat protein inhibits the replication of virus in culture.

Authors:  L Steinaa; A M Sørensen; J O Nielsen; J E Hansen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.

Authors:  Lakshmi Ramakrishna; Krishnamurthy Kumar Anand; Kumarasamypet M Mohankumar; Udaykumar Ranga
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein.

Authors:  Nagadenahalli Byrareddy Siddappa; Mohanram Venkatramanan; Prasanna Venkatesh; Mohanbabu Vijayamma Janki; Narayana Jayasuryan; Anita Desai; Vasanthapuram Ravi; Udaykumar Ranga
Journal:  Retrovirology       Date:  2006-08-18       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.